Amantadine reduces levodopa‐induced dyskinesias in parkinsonian monkeys

Movement Disorders - Tập 13 Số 5 - Trang 798-802 - 1998
Pierre J. Blanchet1, Spyridon Konitsiotis1, Thomas N. Chase1
1Experimental Therapeutics Branch National Institute of Neurological Disorders and Stroke Bethesda, Maryland, U.S.A.

Tóm tắt

AbstractThe antidyskinetic potential of the glutamate NMDA receptor channel blocker amantadine was evaluated in four levodopa‐primed parkinsonian monkeys using two different regimens (1.25 or 2.5 mg/kg administered subcutaneously twice daily for 3–6 days). When administered with a relatively low dose of levodopa, amantadine produced a near‐total suppression of choreiform dyskinesias and a substantial reduction in dystonic dyskinesias at the expense of a significant reduction in antiparkinsonian response. With a high dose of levodopa, amantadine had a smaller but still significant effect on dyskinesias without altering the antiparkinsonian response. These results lend support to the view that glutamate receptormediated mechanisms contribute to levodopa‐induced dyskinesias. They also suggest that amantadine could alleviate such complications in parkinsonian patients, especially with careful dose optimization.

Từ khóa


Tài liệu tham khảo

10.1016/0006-8993(95)00924-3

10.1002/ana.410390505

10.1016/0922-4106(91)90113-V

Blanchet P, 1993, Differential effect of selective D‐1 and D‐2 dopamine receptor agonists on levodopa‐induced dyskinesia in 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐exposed monkeys, J Pharmacol Exp Ther, 267, 275

10.1212/WNL.49.3.711

10.1002/mds.870110516

Rajput AH, 1997, Amantadine ameliorates levodopa induced dyskinesia [Abstract], Neurology, 48, A328

10.1097/00002826-199310000-00004

10.1016/0014-2999(73)90132-5

10.1111/j.1476-5381.1996.tb15736.x

Kulisevsky J, 1990, Therapy of Parkinson's Disease, 143

10.1002/ddr.430290309

Jackisch R, 1992, Studies on the mechanism of action of the antiparkinsonian drugs memantine and amantadine: no evidence for direct dopaminomimetic or antimuscarinic properties, Arch Int Pharmacodyn Ther, 320, 21

10.1016/0014-2999(85)90564-3

10.1016/0014-2999(90)90066-F

10.1016/S0304-3940(97)00355-8

10.1016/0091-3057(89)90372-9

10.1016/0014-2999(90)94802-5

10.1016/0006-8993(93)90694-I

Thông tin
Thông tin xuất bản

Movement Disorders

Tập 13 Số 5

798-802

Thông tin tác giả